Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 12 July 2022 to Question 31781 on Evusheld, whether patient groups representing people who are (a) clinically vulnerable, (b) clinically extremely vulnerable and (c) immunosuppressed have been consulted on the rollout of Evusheld.

The Department has met with stakeholder representatives through the Therapeutics Clinical Review Panel and the Antivirals and Therapeutics Taskforce Engagement Board. These meetings discussed progress on treatments for high risk patient groups, including Evusheld.